Roche shares fall after poster highlights effects of obesity drug

Roche has been throwing itself into the hottest field in pharmaceuticals — obesity drugs — following a series of trial failures in cancer and Alzheimer’s disease.

Shares of Roche fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine.

The poster, released as part of this week’s European Association for the Study of Diabetes annual meeting, showed side effects including nausea, vomiting and diarrhoea for Roche’s injectable drug, CT-388. The stock fell as much as 4.5% in Zurich on Monday.